

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/192937 A1

(43) International Publication Date
22 September 2022 (22.09.2022)

(51) International Patent Classification:

A61K 39/095 (2006.01) *C07K 16/12* (2006.01)
A61K 31/739 (2006.01) *A61P 31/04* (2006.01)
A61K 31/702 (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/AU2022/050213

(22) International Filing Date:

14 March 2022 (14.03.2022)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/161,399 15 March 2021 (15.03.2021) US

(71) Applicants: **GRIFFITH UNIVERSITY** [AU/AU];
170 Kessels Road, Nathan, Queensland 4111 (AU).
UNIVERSITY OF IOWA RESEARCH FOUNDATION
[US/US]; 200 South Capitol Street, 2660 University Capitol
Centre, Iowa City, Iowa 52242 (US).

(72) Inventors: **JENNINGS, Michael**; c/o Griffith University,
170 Kessels Road, Nathan, Queensland 4111 (AU). **JEN,
Freda (En-Chi)**; c/o Griffith University, 170 Kessels Road,
Nathan, Queensland 4111 (AU). **SEIB, Kate**; c/o Griffith
University, 170 Kessels Road, Nathan, Queensland 4111
(AU). **SEMCHENKO, Evgeny**; c/o Griffith University,
170 Kessels Road, Nathan, Queensland 4111 (AU). **KIE-
FEL, Milton**; c/o Griffith University, 170 Kessels Road,
Nathan, Queensland 4111 (AU). **APICELLA, Michael**; c/
o The University of Iowa, 200 South Capitol St., 2660 Uni-
versity Capitol Centre, Iowa City, Iowa 52242 (US).

(74) Agent: **DAVIES COLLISON CAVE PTY LTD**; Level
10, 301 Coronation Drive, Milton, Queensland 4064 (AU).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: PATHOGEN MOIETIES AND USES THEREOF

(57) Abstract: This disclosure relates generally to *Neisseria* surface moieties. More particularly, the present disclosure relates to oligosaccharides corresponding to *Neisseria* lipooligosaccharides and to chimeric molecules comprising these moieties for eliciting an immune response to *Neisseria* organisms and/or for treating or inhibiting the development of *Neisseria* infections.

WO 2022/192937 A1